Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Taysha Gene Therapies (TSHA) Change in Account Payables: 2020-2024

Historic Change in Account Payables for Taysha Gene Therapies (TSHA) over the last 5 years, with Dec 2024 value amounting to -$2.9 million.

  • Taysha Gene Therapies' Change in Account Payables rose 48.48% to -$1.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $469,000, marking a year-over-year increase of 117.72%. This contributed to the annual value of -$2.9 million for FY2024, which is 27.23% down from last year.
  • Per Taysha Gene Therapies' latest filing, its Change in Account Payables stood at -$2.9 million for FY2024, which was down 27.23% from -$2.3 million recorded in FY2023.
  • Over the past 5 years, Taysha Gene Therapies' Change in Account Payables peaked at $14.5 million during FY2021, and registered a low of -$7.8 million during FY2022.
  • Its 3-year average for Change in Account Payables is -$4.3 million, with a median of -$2.9 million in 2024.
  • Its Change in Account Payables has fluctuated over the past 5 years, first surged by 639.11% in 2021, then slumped by 153.84% in 2022.
  • Yearly analysis of 5 years shows Taysha Gene Therapies' Change in Account Payables stood at $2.0 million in 2020, then surged by 639.11% to $14.5 million in 2021, then slumped by 153.84% to -$7.8 million in 2022, then soared by 70.59% to -$2.3 million in 2023, then fell by 27.23% to -$2.9 million in 2024.